Processa Pharmaceuticals

Stamp of approval
#Phase II trial #Processa Pharmaceuticals #US Food and Drug Administration (FDA)

FDA clears Phase II study of VT-7208 in chronic spontaneous urticaria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase II study of Processa Pharmaceuticals’ VT-7208 in chronic spontaneous urticaria (CSU).  Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase II proof-of-concept programmes, including… Read More

#News #Regulatory

#Mergers and acquisitions #Processa Pharmaceuticals #Vidya Therapeutics

Processa Pharmaceuticals buys Vidya Therapeutics

Processa Pharmaceuticals has acquired Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases.  The product is initially focused on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS).  Concurrent… Read More

#Business & Investment #News